EHRA Premium Access

ICD indications in specific settings

Event: EHRA 2018
Topic: Implantable Cardioverter / Defibrillator
Session type: Debate Session
Date: 18 March 2018
Time: 16:30 - 18:00

Session

12 presentations in this session

Opening question

Thumbnail

Primary prevention in non-ischaemic cardiomyopathy - PRO

Speaker: Professor J. Nielsen (Aarhus N, DK)
Thumbnail

Primary prevention in non-ischaemic cardiomyopathy - CON

Speaker: Professor J. Poole (Seattle, US)
Thumbnail

Primary prevention in non-ischaemic cardiomyopathy - Rebuttal PRO

Thumbnail

Primary prevention in non-ischaemic cardiomyopathy - Rebuttal CON

Thumbnail

Chairperson conclusion & Closing question

Thumbnail

Ischaemic heart disease, LVEF>35% and stable ventricular tachycardia - PRO

Speaker: Associate Professor C. Israel (Bielefeld, DE)
Thumbnail

Ischaemic heart disease, LVEF>35% and stable ventricular tachycardia - CON

Speaker: Professor C. Sticherling (Basel, CH)
Thumbnail

Ischaemic heart disease, LVEF>35% and stable ventricular tachycardia - Rebuttal PRO.

Thumbnail

4 speakers from this session

Professor Jens Cosedis Nielsen

Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N (Denmark)
16 presentations
3 followers

Professor Jeanne Poole

University of Washington, Seattle (United States of America)
6 presentations
1 follower

Associate Professor Carsten W Israel

Bethel-Clinic, Bielefeld (Germany)
20 presentations
3 followers

Professor Christian Sticherling

University Hospital Basel, Basel (Switzerland)
11 presentations
0 follower

This platform is supported by

logo Novo Nordisk